<DOC>
	<DOCNO>NCT00475904</DOCNO>
	<brief_summary>The purpose study compare EpiCept™ NP-1 Topical Cream ( 2 % ketamine / 4 % amitriptyline ) v . Oral Gabapentin treatment Postherpetic Neuralgia ( PHN )</brief_summary>
	<brief_title>A Comparison EpiCept™ NP-1 Topical Cream v . Oral Gabapentin Postherpetic Neuralgia ( PHN )</brief_title>
	<detailed_description>This phase II , multicenter , double-blind , randomize , placebo-controlled , parallel group study NP-1 oral gabapentin approximately 500 patient PHN . Adult patient pain result PHN meeting eligibility requirement screen 7 day determine average daily pain intensity . Qualifying patient randomize 2:2:1 basis NP-1 , oral gabapentin , placebo . The treatment period 4-Weeks .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>Amitriptyline , perphenazine drug combination</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Adult patient pain ≥ 3 month follow onset herpes zoster rash Clinically significant intercurrent illness ( e.g. , endocrine , cardiac , hepatic , renal , neurologic , hematologic , skeletal ) investigator determines could interfere efficacy safety assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Post Herpetic Neuralgia</keyword>
	<keyword>PHN</keyword>
	<keyword>Neuropathy</keyword>
	<keyword>Nerve Pain</keyword>
	<keyword>Topical</keyword>
</DOC>